ArticleEuropean journal of medical research2025
Fecal sulfatide as a non-invasive biomarker for predicting coronary heart disease.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Revisiting Alzheimer's Disease Through the Somatostatin-Mitochondria Axis.Molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThe study aimed to investigate a non-invasive biomarker for predicting coronary heart disease by analyzing fecal sulfatide levels.
methodsA retrospective study was conducted on 593 patients with coronary heart disease, divided into acute myocardial infarction (AMI), unstable angina pectoris (UAP), and stable angina pectoris groups (SAP), and a control group of 200 healthy adults. General information was collected for analysis, and fecal sulfatide levels were compared among groups. Binary logistic regression analysis assessed the correlation between fecal sulfatide levels and coronary heart disease. Statistical analyses were performed to evaluate the risk factors, and predictive value was assessed using receiver operating characteristic (ROC) curves.
resultsStatistically significant differences were observed in the characteristics of age, complete blood cell count, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol between the group of patients with coronary heart disease and the control group (P < 0.05). Noteworthy, fecal sulfatide levels were notably higher in coronary heart disease groups. Furthermore, fecal sulfatide levels in AMI group significantly exceeded those in SAP and UAP groups (P < 0.05). Multivariate logistic regression analysis identified fecal sulfatide as an independent risk factor for coronary heart disease, with an area under the ROC curve of 0.893 (95% CI 0.869, 0.921), indicating strong predictive value.
conclusionsFecal sulfatide may serve as a novel, non-invasive biomarker for early coronary heart disease prediction and risk stratification. However, the retrospective and single-center design of this study limits the generalizability of the results, and future large-scale, multi-center prospective studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.